<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Oncology</title><link>https://nrouizem.github.io/test/oncology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/oncology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Fri, 14 Mar 2025 01:17:21 +0000</lastBuildDate><item><title>How atogepant trials are capturing migraine’s real-world impact</title><link>https://www.drugdiscoverytrends.com/how-atogepant-trials-are-capturing-migraines-real-world-impact/</link><description>Recent studies on atogepant have revealed the complexities of migraines, highlighting how clinical trials often fail to capture the dynamic, lived experiences of patients. These findings pave the way for more effective treatments by considering the unpredictable nature of migraines.</description><pubDate>Tue, 28 Jan 2025 01:30:14 +0000</pubDate></item><item><title>How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection</title><link>https://www.drugdiscoverytrends.com/how-an-engineered-algae-based-biologic-aims-to-break-the-annual-5b-cycle-of-c-diff-reinfection/</link><description>Researchers are developing an engineered algae-based biologic to combat Clostridioides difficile, a superbug responsible for 29,000 U.S. deaths each year due to severe infections. This innovative approach aims to disrupt the recurring cycle of C. diff reinfection, which costs the healthcare system approximately $5 billion annually.</description><pubDate>Thu, 30 Jan 2025 05:06:20 +0000</pubDate></item><item><title>Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years</title><link>https://www.drugdiscoverytrends.com/lillys-fda-approval-for-omvoh-close-up-nearly-90-of-one-year-responders-maintained-remission-through-two-years/</link><description>The FDA has approved Omvoh (mirikizumab-mrkz) for Crohn's disease, marking its second IBD authorization in 2023 and the first biologic to launch with Phase 3 two-year efficacy data in over 15 years. In the VIVID-1 trial, 53% of patients treated with Omvoh achieved clinical remission at one year, significantly outperforming the 36% remission rate in the placebo group.</description><pubDate>Fri, 31 Jan 2025 19:00:44 +0000</pubDate></item><item><title>How 3T Biosciences’ platform targets immunologically cold solid tumors</title><link>https://www.drugdiscoverytrends.com/3t-biosciences-targeted-strategy-for-mss-colorectal-cancer/</link><description>3T Biosciences is addressing the challenge of immunotherapy resistance in solid tumors, particularly focusing on microsatellite stable colorectal cancer (MSS CRC), which shows a high failure rate to respond to existing treatments. Their innovative platform aims to target immunologically cold solid tumors, potentially improving therapeutic outcomes in oncology.</description><pubDate>Sat, 01 Feb 2025 05:12:51 +0000</pubDate></item><item><title>Landmark Bio’s mission to prevent cell therapy ‘do-overs’</title><link>https://www.drugdiscoverytrends.com/landmark-bios-mission-to-prevent-cell-therapy-do-overs/</link><description>Landmark Bio aims to reduce the likelihood of biotech startups needing to redo their cell therapy trials by emphasizing the importance of scalable manufacturing from the outset. The company highlights that many researchers rush their products into human testing without adequate preparation, leading to potential setbacks in their development.</description><pubDate>Tue, 04 Feb 2025 15:58:57 +0000</pubDate></item><item><title>How to know if your biopharma company is ‘data ready’ and why it matters</title><link>https://www.drugdiscoverytrends.com/how-to-know-if-your-biopharma-company-is-data-ready-and-why-it-matters/</link><description>Researchers are examining a collection of ancient scrolls, potentially linked to Julius Caesar's father-in-law, which were buried during the eruption of Mount Vesuvius in 79 CE. These scrolls, discovered in the 1800s and meticulously preserved, offer a unique glimpse into history as experts work to decipher their contents.</description><pubDate>Sat, 08 Feb 2025 18:20:30 +0000</pubDate></item><item><title>Avoiding aggregates: How new technology is helping mAb developers monitor a vital CQA</title><link>https://www.drugdiscoverytrends.com/avoiding-aggregates-how-new-technology-is-helping-mab-developers-monitor-a-vital-cqa/</link><description>The monoclonal antibodies (mAbs) market, valued at over $330 billion, is projected to exceed $660 billion by 2030, driven by a growing research pipeline. Developers are increasingly focused on overcoming challenges related to measuring and maintaining critical quality attributes (CQAs) to ensure product efficacy and safety.</description><pubDate>Sat, 08 Feb 2025 19:54:03 +0000</pubDate></item><item><title>For sparse data classification, VersAI’s Extreme AutoML is more accurate and orders of magnitude faster than Google’s AutoML</title><link>https://www.drugdiscoverytrends.com/for-sparse-data-classification-versais-extreme-automl-is-orders-of-magnitude-faster-than-googles-automl/</link><description>Verseon's new AI technology, VersAI, is proving to be a faster and more accurate alternative to Google's AutoML for predictive modeling in sparse data environments. The technology's performance was highlighted in a recent preprint by Verseon researchers and a collaborator from the Missouri University of Science and Technology.</description><pubDate>Sun, 09 Feb 2025 19:59:12 +0000</pubDate></item><item><title>Complexity’s counterpoint: Understanding protocol optimization</title><link>https://www.drugdiscoverytrends.com/complexitys-counterpoint-understanding-protocol-optimization/</link><description>The clinical research landscape is increasingly characterized by complex protocols featuring an expanding number of endpoints and procedures throughout all trial phases and therapeutic areas. This trend highlights the need for effective protocol optimization to manage the sophistication of modern trial designs.</description><pubDate>Mon, 10 Feb 2025 20:33:52 +0000</pubDate></item><item><title>Flatiron Health sees shift from “what if” to “what is” in real-world evidence in oncology</title><link>https://www.drugdiscoverytrends.com/flatiron-health-sees-shift-from-what-if-to-what-is-in-real-world-evidence-in-oncology/</link><description>Flatiron Health is transforming cancer care by transitioning from speculative discussions about AI in healthcare to a focus on tangible results in real-world evidence, according to Blythe Adamson. The company is witnessing a significant reduction in skepticism following the advancements brought on by AI technologies like ChatGPT.</description><pubDate>Wed, 12 Feb 2025 03:39:41 +0000</pubDate></item><item><title>With Deep Research, the CEO of OMNY Health says we’re still ‘in the first inning’ of AI-assisted research</title><link>https://www.drugdiscoverytrends.com/with-deep-research-the-ceo-of-omny-health-says-were-still-in-the-first-inning-of-ai-assisted-research/</link><description>OpenAI's Deep Research tool has the potential to greatly enhance internet-based research by streamlining mundane tasks through AI-assisted inquiries. The CEO of OMNY Health believes that the application of such technology is still in its early stages, likening the journey to being "in the first inning" of a game.</description><pubDate>Fri, 14 Feb 2025 00:05:54 +0000</pubDate></item><item><title>Atropos Health CEO Dr. Brigham Hyde on closing healthcare’s evidence gap with AI-driven insight</title><link>https://www.drugdiscoverytrends.com/atropos-health-ceo-dr-brigham-hyde-on-closing-healthcares-evidence-gap-with-ai-driven-insight/</link><description>Dr. Brigham Hyde, CEO and cofounder of Atropos Health, aims to bridge the "evidence gap" in healthcare decision-making by leveraging AI-driven insights to improve data utilization in clinical contexts. The company's approach addresses the challenges posed by incomplete guidance from clinical trials, enhancing the quality of healthcare decisions.</description><pubDate>Fri, 14 Feb 2025 03:09:10 +0000</pubDate></item><item><title>Rosnilimab phase 2b trial shows promise in treating RA</title><link>https://www.drugdiscoverytrends.com/rosnilimab-phase-2b-trial-shows-promise-in-treating-ra/</link><description>A recent phase 2b trial has demonstrated that rosnilimab, a novel treatment for rheumatoid arthritis (RA), shows promise by specifically targeting the PD-1 pathway to reset the immune system. This approach could offer a new option for patients who struggle to achieve long-term remission with existing therapies.</description><pubDate>Wed, 19 Feb 2025 14:07:47 +0000</pubDate></item><item><title>The challenge of AI inventorship in healthcare</title><link>https://www.drugdiscoverytrends.com/the-challenge-of-ai-inventorship-in-healthcare/</link><description>Generative AI is revolutionizing drug discovery by rapidly identifying new therapeutics and reducing R&amp;D timelines significantly, with several AI-assisted drugs already in clinical trials. However, the rise of AI in healthcare also brings challenges to patent protection and inventorship for these innovative therapies.</description><pubDate>Fri, 21 Feb 2025 14:15:42 +0000</pubDate></item><item><title>Redefining vaccine trial recruitment</title><link>https://www.fiercebiotech.com/resource/redefining-vaccine-trial-recruitment</link><description>Avacare Clinical Research Network's new white paper highlights innovative, data-driven strategies to tackle recruitment challenges and boost diversity in vaccine trials, ensuring more efficient and representative study outcomes. Sponsored by Avacare, the resource offers actionable insights for optimizing trial design and participant engagement through cutting-edge approaches.</description><pubDate>Wed, 26 Feb 2025 14:26:35 +0000</pubDate></item><item><title>Solutions for CAR-Engineered Cell Characterization</title><link>https://www.fiercebiotech.com/resource/solutions-car-engineered-cell-characterization</link><description>Cell Signaling Technology (CST) has unveiled purpose-built tools, including recombinant antibodies targeting scFv linkers like G4S and Whitlow/218, to accelerate CAR-engineered cell characterization and development. The solutions aim to bypass the costly, time-intensive process of anti-idiotype antibody creation while streamlining workflows for researchers.</description><pubDate>Wed, 26 Feb 2025 14:49:25 +0000</pubDate></item><item><title>COTA Healthcare announces AI milestone in real-world oncology data</title><link>https://www.drugdiscoverytrends.com/cota-healthcare-announces-ai-milestone-in-real-world-oncology-data/</link><description>COTA Healthcare has announced a significant advancement in real-world oncology data through its new generative AI platform, which enhances the accuracy and profitability of large-scale cancer data curation. This breakthrough represents a transformative shift from earlier industry efforts to automate the labor-intensive process of real-world data abstraction.</description><pubDate>Wed, 26 Feb 2025 19:00:13 +0000</pubDate></item><item><title>Successful Scale-Up Of An Upstream Viral Vector Process Using An Adherent Platform</title><link>https://www.fiercebiotech.com/premium/webinar/1368645</link><description>Cytiva's webinar, featuring Brian Gardell, explores scaling challenges in viral vector manufacturing for cell and gene therapies, emphasizing the need for cost-effective, standardized processes to meet clinical demand. The session highlights a case study on successfully scaling a helper-dependent adenovirus (HDAd) production process from bench optimization to commercial readiness using adherent culture platforms.</description><pubDate>Thu, 27 Feb 2025 16:40:10 +0000</pubDate></item><item><title>Finding Patients, Closing Treatment Gaps, and Building Better Messaging through AI and Real-World Data</title><link>https://www.fiercebiotech.com/premium/webinar/1368842</link><description>OM1's upcoming webinar, featuring experts Joseph Zabinski and Kathryn Starzyk, explores how AI-driven digital phenotyping and real-world data can help pharmaceutical teams identify underserved patient populations and align therapies with unmet clinical needs. The session will demonstrate strategies to bridge treatment gaps, refine market messaging, and ensure therapies reach overlooked communities through advanced analytics.</description><pubDate>Thu, 06 Mar 2025 20:09:20 +0000</pubDate></item><item><title>AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data</title><link>https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data</link><description>AstraZeneca's cancer drug Imfinzi is poised to drive significant growth in 2025, with regulators set to decide on its expanded use in treating stomach and bladder cancers. The blockbuster therapy generated over $4.7 billion in sales last year, cementing its role as a key revenue driver for the pharmaceutical giant.</description><pubDate>Fri, 07 Mar 2025 13:58:56 +0000</pubDate></item><item><title>Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II</title><link>https://www.biospace.com/drug-development/novos-studies-of-glp-1s-for-addiction-limited-to-ongoing-phase-ii</link><description>Novo Nordisk clarified it has no additional clinical trials exploring GLP-1 drugs for addiction beyond a Phase II study testing semaglutide and two other medications, despite recent speculation. The trial, which includes alcohol use disorder as a secondary endpoint, remains the sole focus for potential substance use applications, following a company official’s earlier comments.</description><pubDate>Fri, 07 Mar 2025 14:29:30 +0000</pubDate></item><item><title>At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis</title><link>https://endpts.com/at-300m-kardigan-startup-former-myokardia-team-unveils-its-first-drug-and-it-comes-from-ionis/</link><description>Former MyoKardia executives launched a heart health biotech startup with $300 million in funding, leveraging undisclosed partnerships to secure in-licensed clinical-stage assets for cardiac therapies. The stealth-mode company remains tight-lipped about specific deals but signals a focus on advancing innovative treatments, attracting attention for its seasoned leadership and strategic collaborations.</description><pubDate>Fri, 07 Mar 2025 16:16:52 +0000</pubDate></item><item><title>Roche launches new Boston center; NIH centralizes peer review</title><link>https://www.biopharmadive.com/news/roche-boston-center-nih-peer-review-pfizer-james-list/741901/</link><description>Swiss pharma giant Novartis announced plans to centralize its cardiometabolic drug research at a new Allston, Massachusetts, hub, signaling a strategic focus on heart and metabolic disease innovation. Meanwhile, AskBio progressed a mid-phase gene therapy trial, and Pfizer tapped a GLP-1 expert, intensifying competition in the weight-loss and diabetes therapeutics race.</description><pubDate>Fri, 07 Mar 2025 16:20:00 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody</title><link>https://endpts.com/sun-pharma-to-acquire-checkpoint-therapeutics-and-its-anti-pd-l1-antibody/</link><description>Checkpoint Therapeutics has pivoted from seeking a partnership for its newly approved cancer drug to being acquired outright by India’s Sun Pharma in a strategic immuno-oncology expansion. The deal, valued at $4.10 per share, marks a swift exit for Checkpoint and reinforces Sun Pharma’s growing footprint in cutting-edge cancer therapies.</description><pubDate>Mon, 10 Mar 2025 12:20:53 +0000</pubDate></item><item><title>Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout</title><link>https://www.biospace.com/drug-development/novo-dips-after-cagrisemas-latest-lower-than-expected-weight-loss-readout</link><description>New clinical trial results revealed CagriSema, a weight-loss drug from Novo, achieved 15.7% weight reduction in diabetic patients over 68 weeks but delivered a disappointing 22.7% in non-diabetic patients by December 2024, falling short of the company’s projected 25% efficacy. The underwhelming performance in non-diabetic trials raises questions about the drug’s competitive edge in the crowded obesity treatment market.</description><pubDate>Mon, 10 Mar 2025 14:14:35 +0000</pubDate></item><item><title>Trevi Therapeutics stock soars on Phase 2a chronic cough data</title><link>https://endpts.com/trevi-therapeutics-stock-soars-on-phase-2a-chronic-cough-data/</link><description>Trevi Therapeutics' chronic cough drug demonstrated a 57% reduction in 24-hour cough frequency versus placebo in a Phase 2a trial, outperforming investor expectations and sparking a 40% surge in its stock ($TRVI) at market open. The breakthrough underscores the treatment’s potential and has ignited optimism among investors about the company’s clinical and commercial prospects.</description><pubDate>Mon, 10 Mar 2025 15:51:40 +0000</pubDate></item><item><title>Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash</title><link>https://www.biospace.com/drug-development/mineralys-hypertension-drug-drops-blood-pressure-in-phase-ii-iii-setting-up-market-clash</link><description>Mineralys Therapeutics saw its stock surge over 50% after announcing successful Phase 2 trial results for its hypertension drug, which significantly reduced blood pressure in patients across two clinical studies. The promising data positions the therapy as a potential leader in the $30 billion hypertension market, heightening investor interest in the company’s future regulatory and commercial plans.</description><pubDate>Mon, 10 Mar 2025 16:11:28 +0000</pubDate></item><item><title>Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial</title><link>https://endpts.com/mired-in-low-expectations-novo-braces-for-upcoming-cagrisema-head-to-head-trial/</link><description>Novo Nordisk's weight loss drug CagriSema underperformed in late-stage trials, missing analyst expectations and marking its second high-profile clinical setback. With mounting pressure on the candidate, its success in future trials has become critical for the company’s competitive pipeline.</description><pubDate>Mon, 10 Mar 2025 16:20:49 +0000</pubDate></item><item><title>Beam shares promising first clinical data on gene editing treatment</title><link>https://endpts.com/beam-shares-promising-first-clinical-data-on-gene-editing-treatment/</link><description>Beam Therapeutics' experimental gene-editing therapy demonstrated promising results in a small trial, reducing mutant proteins linked to lung-damaging alpha-1 antitrypsin deficiency and boosting corrected protein levels in nine participants. The early data underscores the treatment's potential as a one-time fix for the genetic disorder, though the article does not mention any business deals, partnerships, or mergers.</description><pubDate>Mon, 10 Mar 2025 16:42:30 +0000</pubDate></item><item><title>BioNTech's shares dip after posting lukewarm revenue guidance</title><link>https://endpts.com/biontechs-shares-dip-after-posting-lukewarm-revenue-guidance/</link><description>BioNTech shares fell 2% after projecting lower 2025 revenues, citing reduced COVID-19 vaccine demand and oversupply challenges despite a solid $4.2 billion revenue in 2023. The company plans to pivot toward advancing cancer treatments and cost-cutting measures while preparing for new vaccine launches to offset declining pandemic-related sales.</description><pubDate>Mon, 10 Mar 2025 19:37:01 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item><item><title>New Flagship startup aims to trailblaze ‘AI science factories’</title><link>https://endpts.com/new-flagship-startup-aims-to-trailblaze-ai-science-factories/</link><description>Flagship Pioneering unveiled Lila Sciences, a new startup backed by $200 million, aiming to develop "scientific superintelligence" by integrating AI with cutting-edge scientific research. The venture assembles a cross-disciplinary team of scientists and AI experts under Flagship’s venture-creation model to accelerate transformative breakthroughs in biotechnology and drug discovery.</description><pubDate>Mon, 10 Mar 2025 20:39:42 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients</title><link>https://endpts.com/arvinas-and-pfizers-protac-vepdegestrant-works-in-subset-of-breast-cancer-patients/</link><description>Arvinas and Pfizer's partnered experimental breast cancer drug, vepdegestrant, failed to outperform existing therapies in the Phase 3 VERITAC-2 trial, casting doubt on its competitive potential. The results highlight challenges for the collaboration’s aim to deliver a differentiated treatment in the crowded protein degrader landscape.</description><pubDate>Tue, 11 Mar 2025 11:56:49 +0000</pubDate></item><item><title>The Shape of a Pandemic: Boom, Bust and Recover</title><link>https://www.biospace.com/business/the-shape-of-a-pandemic-boom-bust-and-recover</link><description>As the world marks five years since the onset of COVID-19, the pandemic’s ripple effects continue to reshape global health, innovation, and daily life, with the life sciences sector undergoing unprecedented transformation. While no specific business deals are cited, the article underscores how the crisis catalyzed lasting shifts in biomedical research, public health strategies, and societal resilience, leaving a profound legacy of change for individuals and industries alike.</description><pubDate>Tue, 11 Mar 2025 13:56:41 +0000</pubDate></item><item><title>Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug</title><link>https://www.biospace.com/drug-development/pfizer-arvinas-post-mixed-late-stage-breast-cancer-data-for-closely-watched-protac-drug</link><description>Vepdegestrant’s mixed trial results—stalling on broad progression-free survival but showing promise in a niche patient group—sparked a 43% plunge in Arvinas’ stock, with analysts casting doubt on the drug's long-term viability. While no new deals were announced, the setback raises questions about the company’s ability to attract future partnerships or advance the drug’s commercial prospects.</description><pubDate>Tue, 11 Mar 2025 14:08:28 +0000</pubDate></item><item><title>Corrected: Merck opens billion-dollar US facility to make Gardasil</title><link>https://endpts.com/merck-opens-billion-dollar-facility-to-make-bladder-cancer-immunotherapy/</link><description>Merck has launched a new North Carolina-based manufacturing facility to produce HPV vaccines, including Gardasil and Gardasil 9, to meet rising global demand for cervical cancer prevention. The plant’s opening aligns with Merck’s strategy to expand production capacity amid increasing vaccine rollout efforts worldwide.</description><pubDate>Tue, 11 Mar 2025 14:50:06 +0000</pubDate></item><item><title>2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M</title><link>https://www.biopharmadive.com/news/2seventy-bio-bristol-myers-deal-abecma-bluebird/742142/</link><description>2Seventy Bio's recent acquisition has terminated its brief stint as an independent firm, marking the end of a turbulent period marked by strategic restructuring and asset sales. The company, which shed research segments and saw its market value plummet by nearly 100%, now shifts focus under new ownership amid financial struggles.</description><pubDate>Tue, 11 Mar 2025 16:05:00 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Roche broadens obesity drug plans with $1.65B Zealand deal</title><link>https://www.biopharmadive.com/news/roche-zealand-license-obesity-drug-amylin-petrelinitide/742278/</link><description>Swiss pharma gains access to an experimental amylin-targeting treatment through a new deal, planning to test it in combination with drugs acquired from Carmot. This partnership aims to enhance their therapeutic offerings and advance their research pipeline.</description><pubDate>Wed, 12 Mar 2025 16:20:00 +0000</pubDate></item><item><title>Ono earmarks $940m to gain rare blood cancer therapy from Ionis</title><link>https://www.pharmaceutical-technology.com/news/ono-earmarks-940m-to-gain-rare-blood-cancer-therapy-from-ionis/</link><description>Ono Pharmaceuticals has acquired the global rights to sapablursen, an RNA-targeting therapy developed by Ionis for the treatment of polycythemia vera (PV). This strategic deal enhances Ono's portfolio in addressing blood-related disorders.</description><pubDate>Wed, 12 Mar 2025 16:46:44 +0000</pubDate></item><item><title>Vivace closes $35m in Series D for cancer drug development</title><link>https://www.pharmaceutical-technology.com/news/vivace-35m-cancer-drug-vt3989/</link><description>Vivace Therapeutics has successfully raised $35 million in a Series D financing round aimed at advancing the clinical development of its cancer treatment, VT3989. The funding will bolster the company's efforts to bring this promising drug to market.</description><pubDate>Thu, 13 Mar 2025 11:12:46 +0000</pubDate></item><item><title>Telix’s new lead-212 generator could dispel medical isotope scalability hurdles</title><link>https://www.pharmaceutical-technology.com/news/telixs-new-lead-212-generator-could-dispel-medical-isotope-scalability-hurdles/</link><description>Lead-212-based alpha emitters hold potential for cancer therapies but face challenges in commercial supply. Efforts are being made to overcome these obstacles to harness their therapeutic benefits effectively.</description><pubDate>Thu, 13 Mar 2025 11:34:09 +0000</pubDate></item><item><title>Montara Therapeutics adds $20M to seed fundraise for neurology pipeline</title><link>https://endpts.com/montara-therapeutics-adds-20m-to-seed-fundraise-for-neurology-pipeline/</link><description>Montara Therapeutics has secured $20 million in expanded seed financing to further develop its preclinical CNS candidates, aiming to tackle safety issues that have hindered research and development in the field. This funding will support the company's efforts to advance innovative solutions in central nervous system therapies.</description><pubDate>Thu, 13 Mar 2025 12:00:29 +0000</pubDate></item><item><title>Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies</title><link>https://endpts.com/acelyrin-pliant-turn-to-poison-pill-as-kevin-tangs-concentra-pursues-both-companies/</link><description>Acelyrin and Pliant Therapeutics have implemented "poison pill" strategies in response to potential takeover interest from Kevin Tang’s Concentra Biosciences. This move comes as Acelyrin, an immunology biotech, grapples with several clinical challenges.</description><pubDate>Thu, 13 Mar 2025 14:50:24 +0000</pubDate></item></channel></rss>